AstraZeneca's Breast Cancer Drug Delivers Strong Results, Boosting Company

AstraZeneca reported positive results from a trial on drug datopotamab deruxtecan in breast cancer patients, showing a significant improvement compared to chemotherapy. This development led to a 2.6% surge in AstraZeneca's share price, adding nearly £5 billion to its market value.

Articles published about this story
More stories